Abstract 149: Successful Reperfusion After Endovascular Treatment Predicted Favorable Outcome in the Basilar Artery Occlusion Endovascular Intervention versus Standard Medical Treatment (BEST) Trial

Abstract

Background: Several randomized trials have demonstrated a strong benefit of endovascular reperfusion in the anterior circulation strokes. The association between successful reperfusion and outcomes is less well established in acute vertebrobasilar artery occlusions (VBAO). We aim to investigate the association between successful reperfusion and 90-day favorable outcome in BEST trial. Methods: The BEST trial was a multicenter randomized controlled trial of endovascular treatment versus medical treatment alone in VBAO. In the current analysis, we included patients who underwent endovascular treatment in the As-Treated Population of our trial. Successful reperfusion was defined as modified Thrombolysis in Cerebral Infarction Score (mTICI) 2b/3 post-intervention. Favorable outcome was defined as mRS 0-3. Logistic regression was used to investigate the association between successful reperfusion and outcome. Results: The trial was terminated prematurely in September-2017 after enrolling 131 patients due to a high cross-over rate (Control to the ET=14; ET to Control=3). A total of 77 patients received endovascular treatment were included in this analysis. Baseline characteristics and outcome measures according to Intention-To-Treat (IIT), Per-Protocol (PP), and As-Treated (AT) analyses are summarized in Table 1 . Successful reperfusion was achieved in 70.1% (54/77) patients. Multivariable logistic regression adjusted for age and baseline NIHSS score showed that successful reperfusion was significantly associated with favorable outcome at 90 days (adjusted OR, 3.16; 95% CI, 1.05 to 9.48, p=0.04) as well as a strong trend towards lower 90-day mortality (adjusted OR, 0.36; 95% CI, 0.12 to 1.06, p=0.06). Conclusion: Endovascular reperfusion was associated with better 90-day functional outcome and a trend towards lower mortality in the BEST Trial. Table 1: Baseline Characteristics and Outcomes Measures: